FDA Com. Young on OTCs

Rx-to-OTC switches will be one of FDA's priority issues Young said in a Nov. 12 letter to the World Federation of Proprietary Medicine Mfrs. general assembly in Tokyo. Noting that in addition to "tackling" the OTC Review, FDA has nearly finished the DESI program, the letter, read by former FDA Com. Alexander Schmidt, MD, said: "We have not been idle, and you should know that I will engage my staff in equally demanding activities as we move on to other priorities. One of these must involve the switching of Rx drugs to OTC status"